Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 29

1.

Comparative study of gabapentin and isoflavone in menopausal vasomotor symptoms.

Singhal SR, Shullai WK.

J Midlife Health. 2016 Jul-Sep;7(3):132-139.

2.
3.

Is complementary and alternative therapy effective for women in the climacteric period?

Kim MY, Choi SD, Ryu A.

J Menopausal Med. 2015 Apr;21(1):28-35. doi: 10.6118/jmm.2015.21.1.28. Epub 2015 Apr 27. Review.

4.

Safety and efficacy of gabapentin in management of psychosomatic and sexual symptoms in postmenopausal women: A pilot study.

Agarwal N, Singh S, Kriplani A, Bhatla N, Singh N.

J Midlife Health. 2015 Jan-Mar;6(1):10-5. doi: 10.4103/0976-7800.153605.

5.

A systematic review of non-hormonal treatments of vasomotor symptoms in climacteric and cancer patients.

Drewe J, Bucher KA, Zahner C.

Springerplus. 2015 Feb 10;4:65. doi: 10.1186/s40064-015-0808-y. eCollection 2015.

6.

Comparison of Gabapentin with Estrogen for treatment of hot flashes in post-menopausal women.

Allameh Z, Rouholamin S, Valaie S.

J Res Pharm Pract. 2013 Apr;2(2):64-9. doi: 10.4103/2279-042X.117392.

7.

The effect of gabapentin on intensity and duration of hot flashes in postmenopausal women: a randomized controlled trial.

Saadati N, Mohammadjafari R, Natanj S, Abedi P.

Glob J Health Sci. 2013 Sep 10;5(6):126-30. doi: 10.5539/gjhs.v5n6p126.

8.

The use of pregabalin in the treatment of hot flashes.

Nguyen ML.

Can Pharm J (Ott). 2013 Jul;146(4):193-6. doi: 10.1177/1715163513490636. No abstract available.

9.

Breast cancer survivorship issues.

Stan D, Loprinzi CL, Ruddy KJ.

Hematol Oncol Clin North Am. 2013 Aug;27(4):805-27, ix. doi: 10.1016/j.hoc.2013.05.005. Epub 2013 Jun 19. Review.

10.

Impact of dose, frequency of administration, and equol production on efficacy of isoflavones for menopausal hot flashes: a pilot randomized trial.

Crawford SL, Jackson EA, Churchill L, Lampe JW, Leung K, Ockene JK.

Menopause. 2013 Sep;20(9):936-45. doi: 10.1097/GME.0b013e3182829413.

11.

Risk factors, pathophysiology, and treatment of hot flashes in cancer.

Fisher WI, Johnson AK, Elkins GR, Otte JL, Burns DS, Yu M, Carpenter JS.

CA Cancer J Clin. 2013 May;63(3):167-92. doi: 10.3322/caac.21171. Epub 2013 Jan 25. Review.

12.

Treatment options for vasomotor symptoms in menopause: focus on desvenlafaxine.

Umland EM, Falconieri L.

Int J Womens Health. 2012;4:305-19. doi: 10.2147/IJWH.S24614. Epub 2012 Jul 5.

13.

"Symptom-specific or holistic": menopausal symptom management.

Im EO, Ko Y, Hwang H, Chee W.

Health Care Women Int. 2012;33(6):575-92. doi: 10.1080/07399332.2011.646371.

14.

Nighttime awakenings responding to gabapentin therapy in late premenopausal women: a case series.

Guttuso T Jr.

J Clin Sleep Med. 2012 Apr 15;8(2):187-9. doi: 10.5664/jcsm.1776.

15.

Androgen deprivation therapy-associated vasomotor symptoms.

Jones JM, Kohli M, Loprinzi CL.

Asian J Androl. 2012 Mar;14(2):193-7. doi: 10.1038/aja.2011.101. Epub 2012 Jan 30. Review.

16.

Hot flashes: a review of pathophysiology and treatment modalities.

Morrow PK, Mattair DN, Hortobagyi GN.

Oncologist. 2011;16(11):1658-64. doi: 10.1634/theoncologist.2011-0174. Epub 2011 Oct 31. Review.

17.

Mindfulness training for coping with hot flashes: results of a randomized trial.

Carmody JF, Crawford S, Salmoirago-Blotcher E, Leung K, Churchill L, Olendzki N.

Menopause. 2011 Jun;18(6):611-20. doi: 10.1097/gme.0b013e318204a05c.

18.
19.

Nonhormonal management of hot flashes for women on risk reduction therapy.

Sideras K, Loprinzi CL.

J Natl Compr Canc Netw. 2010 Oct;8(10):1171-9.

20.

A2delta ligands gabapentin and pregabalin: future implications in daily clinical practice.

Tzellos TG, Papazisis G, Toulis KA, Sardeli Ch, Kouvelas D.

Hippokratia. 2010 Apr;14(2):71-5.

Supplemental Content

Support Center